4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 30
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Joseph P. Hagan M.B.A. | CEO & Director | 920.73k | N/D | 1969 |
Ms. Crispina Calsada CPA | Chief Financial Officer | 500.87k | N/D | 1970 |
Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 524.79k | N/D | 1961 |
Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/D | N/D | 1969 |
Mr. Daniel J. Penksa | VP of Finance & Controller | N/D | N/D | 1986 |
Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development & Regulatory | N/D | N/D | N/D |
Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/D | N/D | N/D |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de Regulus Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.